Protalix BioTherapeutics Inc (AMEX:PLX)
$ 1.1 -0.15 (-12%) Market Cap: 80.65 Mil Enterprise Value: 62.37 Mil PE Ratio: 55.00 PB Ratio: 2.39 GF Score: 60/100

Q3 2019 Protalix Biotherapeutics Inc Earnings Call Transcript

Nov 07, 2019 / 01:30PM GMT
Release Date Price: $2.3 (-0.86%)
Operator

Good day. And welcome to the Protalix Biotherapeutics Third Quarter 2019 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.

Monique Kosse
LifeSci Advisors, LLC - MD

Thank you. Hello, everyone, and welcome to Protalix Biotherapeutics Third Quarter Earnings Results and Corporate Update Conference Call. With me today are Dror Bashan, Protalix's President and CEO; and Eyal Rubin, Senior Vice President and Chief Financial Officer.

A press release announcing the results is available on Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release, their earnings release and this teleconference, including forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made here today. Factors that could cause actual results to differ are described in the disclaimer and in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot